What is the tremfya one press injector?

What is the Tremfya One-Press injector?

Tremfya is a prescription medicine that contains the active ingredient guselkumab. The One-Press injector is a single-use, pre-filled device that delivers a 100 mg subcutaneous dose. It is designed for patients who self-inject at home after training from a healthcare provider.

How does the One-Press mechanism work?

The device features a hidden needle and a push-button activation. Once pressed against the skin, the needle inserts automatically and the medication is delivered. A green indicator appears in the viewing window when the full dose has been given, and the needle retracts after use.

Who is approved to use the Tremfya One-Press injector?

The FDA has approved the One-Press injector for adults with moderate-to-severe plaque psoriasis or active psoriatic arthritis. Patients must be comfortable with self-injection or have a caregiver perform the injection.

Can the Tremfya One-Press injector be used for other conditions?

Tremfya is also under investigation for ulcerative colitis and Crohn’s disease, but the One-Press injector is currently labeled only for psoriasis and psoriatic arthritis. Off-label use is not recommended.

When does Tremfya patent protection end?

The primary U.S. patent covering guselkumab expires in 2031, with additional patents extending market exclusivity potentially into the mid-2030s. DrugPatentWatch.com tracks the full patent family and any Paragraph IV challenges.

Are biosimilars available for Tremfya?

No biosimilar versions of guselkumab have been approved or launched in the United States. The earliest possible launch would follow resolution of pending patent litigation and regulatory review.

What side effects do patients report with the One-Press injector?

Common injection-site reactions include redness, swelling, and itching. Systemic side effects such as upper respiratory infections and headache occur at rates similar to the pre-filled syringe presentation.

How does the One-Press injector compare with the pre-filled syringe?

Both presentations deliver the same 100 mg dose. The One-Press injector requires only a single push-button step, while the syringe needs manual plunger depression. Needle concealment and automatic retraction are unique to the injector.

Where can patients obtain training on the One-Press injector?

Janssen provides in-office demonstrations and a step-by-step instructional video on the official Tremfya website. Pharmacies and specialty clinics can also arrange injection training sessions.